JP7161475B2 - 官能化ｎａｎｏｌｕｃ阻害剤 - Google Patents

官能化ｎａｎｏｌｕｃ阻害剤 Download PDF

Info

Publication number
JP7161475B2
JP7161475B2 JP2019535843A JP2019535843A JP7161475B2 JP 7161475 B2 JP7161475 B2 JP 7161475B2 JP 2019535843 A JP2019535843 A JP 2019535843A JP 2019535843 A JP2019535843 A JP 2019535843A JP 7161475 B2 JP7161475 B2 JP 7161475B2
Authority
JP
Japan
Prior art keywords
ethyl
amino
oxoethyl
trans
carboxamido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019535843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504754A5 (enExample
JP2020504754A (ja
Inventor
ロデリック ジー フレミング
メアリー ホール
トーマス マクライト
ポンチョ マイセンハイマー
ニディ ナス
マシュー ビー ロバース
ジョエル アール ウォーカー
ウェンフイ ジョウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Publication of JP2020504754A publication Critical patent/JP2020504754A/ja
Publication of JP2020504754A5 publication Critical patent/JP2020504754A5/ja
Application granted granted Critical
Publication of JP7161475B2 publication Critical patent/JP7161475B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G01N21/763—Bioluminescence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2019535843A 2016-12-28 2017-12-28 官能化ｎａｎｏｌｕｃ阻害剤 Active JP7161475B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662439600P 2016-12-28 2016-12-28
US62/439,600 2016-12-28
PCT/US2017/068686 WO2018125992A1 (en) 2016-12-28 2017-12-28 Functionalized nanoluc inhibitors

Publications (3)

Publication Number Publication Date
JP2020504754A JP2020504754A (ja) 2020-02-13
JP2020504754A5 JP2020504754A5 (enExample) 2021-02-12
JP7161475B2 true JP7161475B2 (ja) 2022-10-26

Family

ID=61007855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019535843A Active JP7161475B2 (ja) 2016-12-28 2017-12-28 官能化ｎａｎｏｌｕｃ阻害剤

Country Status (4)

Country Link
US (1) US10815247B2 (enExample)
EP (1) EP3562823B1 (enExample)
JP (1) JP7161475B2 (enExample)
WO (1) WO2018125992A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513694B2 (en) 2015-06-25 2019-12-24 Promega Corporation Thienopyrrole compounds and uses thereof
WO2018125992A1 (en) 2016-12-28 2018-07-05 Promega Corporation Functionalized nanoluc inhibitors
US12181452B2 (en) 2017-09-18 2024-12-31 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US11709156B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved analytical analysis
US11709155B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US12180581B2 (en) 2017-09-18 2024-12-31 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
WO2019232384A1 (en) * 2018-06-01 2019-12-05 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes
US11691976B2 (en) 2018-08-23 2023-07-04 Promega Corporation Coelenterazine analogues
JP6671574B1 (ja) 2018-08-27 2020-03-25 大日本住友製薬株式会社 光学活性なアザビシクロ環誘導体
CN111848657B (zh) * 2019-04-24 2021-12-31 中国科学院上海药物研究所 靶向酪氨酸激酶识别的可逆性荧光化合物及其制备方法和应用
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding
EP4628889A3 (en) 2020-09-24 2025-12-10 Waters Technologies Corporation Chromatographic hardware improvements for the separation of reactive molecules
EP4602045A1 (en) 2022-10-14 2025-08-20 Promega Corporation Coelenterazine analogues
US20250206747A1 (en) 2023-12-20 2025-06-26 Promega Corporation Coelenterazine analogues

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196357A1 (en) 2008-02-20 2010-08-05 Qihong Huang Microrna modulators and method for identifying and using the same
JP2018524334A (ja) 2015-06-25 2018-08-30 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ チエノピロール化合物、及びそのＯｐｌｏｐｈｏｒｕｓ由来ルシフェラーゼの阻害剤としての使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3828535A1 (de) 1988-08-23 1990-03-08 Basf Ag Benzimidazol-2-carbonsaeureanilide, ihre verwendung als lichtschutzmittel fuer organisches material und mit diesen aniliden stabilisiertes organisches material
US5283179A (en) 1990-09-10 1994-02-01 Promega Corporation Luciferase assay method
EP0746544B1 (en) * 1994-02-22 1998-09-09 Merrell Pharmaceuticals Inc. Novel indole derivatives useful to treat estrogen-related neoplasms and disorders
US7268229B2 (en) 2001-11-02 2007-09-11 Promega Corporation Compounds to co-localize luminophores with luminescent proteins
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
FR2897061B1 (fr) 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
US8163910B2 (en) 2007-10-03 2012-04-24 Elitech Holding B.V. Amide-substituted xanthene dyes
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
DK2456864T3 (en) 2009-05-01 2015-12-21 Promega Corp SYNTHETIC OPLOPHORUS luciferases WITH IMPROVED LIGHT MISSION
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
PT2635583E (pt) 2010-11-02 2015-09-11 Promega Corp Derivados da coelenterazina e métodos de utilização da mesma
US8669103B2 (en) 2010-11-02 2014-03-11 Promega Corporation Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
EP2751089B1 (en) 2011-09-02 2018-11-14 Promega Corporation Compounds and methods for assaying redox state of metabolically active cells and methods for measuring nad(p)/nad(p)h
EP2900833B1 (en) 2012-09-26 2018-05-30 Promega Corporation Real-time monitoring
WO2015067302A1 (en) 2013-11-05 2015-05-14 Ecole Polytechnique Federale De Lausanne (Epfl) Sensor molecules and uses thereof
WO2015116867A1 (en) 2014-01-29 2015-08-06 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
US9927430B2 (en) 2014-01-29 2018-03-27 Promega Corporation Pro-substrates for live cell applications
EP3304078B1 (en) 2015-06-05 2022-08-31 Promega Corporation Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements
WO2018125992A1 (en) 2016-12-28 2018-07-05 Promega Corporation Functionalized nanoluc inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196357A1 (en) 2008-02-20 2010-08-05 Qihong Huang Microrna modulators and method for identifying and using the same
JP2018524334A (ja) 2015-06-25 2018-08-30 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ チエノピロール化合物、及びそのＯｐｌｏｐｈｏｒｕｓ由来ルシフェラーゼの阻害剤としての使用

Also Published As

Publication number Publication date
WO2018125992A1 (en) 2018-07-05
EP3562823A1 (en) 2019-11-06
EP3562823B1 (en) 2023-02-08
JP2020504754A (ja) 2020-02-13
US20180222916A1 (en) 2018-08-09
US10815247B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
EP3562823B1 (en) Functionalized nanoluc inhibitors
JP6862368B2 (ja) チエノピロール化合物、及びそのＯｐｌｏｐｈｏｒｕｓ由来ルシフェラーゼの阻害剤としての使用
EP3099691B1 (en) Pro-substrates for live cell applications
US12570654B2 (en) Nanoluc suicide substrates
JP7664336B2 (ja) Ｏｐｌｏｐｈｏｒｕｓルシフェラーゼ由来生物発光性複合体の阻害剤
JP7200102B2 (ja) エネルギー受容体に係留されたセレンテラジン類縁体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220510

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221014

R150 Certificate of patent or registration of utility model

Ref document number: 7161475

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250